Against Wounds and Cellulitis
A new unique bacteriophage , developed at an affiliate of NPO Microgen at Immunopreparat (Ufa), is ready for launch in the pharma market.
It was a unique product, consolidating a few virulent bacteriophages of Enterobacter genus — species E. aerogenes, E. cloacae, E. agglomerans, purified of bacterial metabolites. Phase II clinical trials have already been completed. Its results have evidenced the safety and efficacy of the drug in treatment of surgical infections caused by the above bacteria, and post-operative cellulitis.
Product developers expect to complete phase III clinical trials this year.